Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950225 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL4161693 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL4161692 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL10701473 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL12458464 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL4166853 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL4166859 | 1.00 | FAAH (0.47) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL13950230 | 0.98 | FAAH (0.45) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL12458463 | 0.98 | FAAH (0.45) | FAAHTRPV1DNM1MEN1KMT2A | |
| SCHEMBL10065903 | 0.98 | FAAH (0.45) | FAAHTRPV1DNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158827-B2 | Transfection reagents | Life Technologies Corporation (US) | 2012-04-17 | — | — | US | disclosed |
| US-7915450-B2 | Transfection reagents | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100159593-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090143583-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2009-06-04 | — | — | US | disclosed |
| US-7470817-B2 | Transfection reagents | INVITROGEN CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-7323594-B2 | Transfection reagents | INVITROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070202600-A1 | TRANSFECTION REAGENTS | INVITROGEN CORPORATION (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070202598-A1 | NEW TRANSFECTION REAGENTS | INVITROGEN CORPORATION (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202598-A1 | NEW TRANSFECTION REAGENTS | PHAX, CPS1, HNRNPH3 | FAAH 4765/4885TRPV1 3074/4885DNM1 4088/4885 |
| US-20090143583-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | FAAH 4762/4885TRPV1 3213/4885DNM1 3838/4885 |
| US-20100159593-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | FAAH 4763/4885TRPV1 3215/4885DNM1 3810/4885 |
| US-20070202600-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | FAAH 4767/4885TRPV1 3219/4885DNM1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.